Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed that it bought back 95,200 H shares on 30 June 2026 through the Hong Kong Stock Exchange.

The shares were repurchased at prices between HKD 17.38 and HKD 17.81, translating into an average consideration of HKD 17.713 per share and an aggregate outlay of HKD 1.69 million. All repurchased shares are being held as treasury stock.

Following the transaction, Bao Pharma’s issued share capital (excluding treasury shares) declined to 154.23 million from 154.33 million, representing a 0.06% reduction. Treasury shares now stand at 95,200.

The buyback forms part of a mandate approved by shareholders on 26 May 2026, which authorises the repurchase of up to 15.43 million shares. To date, 0.06% of this limit has been utilised. Under Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 30 July 2026.